School of Psychology, Flinders University, Adelaide, SA, Australia.
Eur J Cancer Care (Engl). 2012 Jan;21(1):98-106. doi: 10.1111/j.1365-2354.2011.01279.x. Epub 2011 Aug 18.
While 50% of cancer patients use complementary therapies (CT) during treatment, few studies have examined why individuals choose not to use CT. This study aimed to address this gap in knowledge using a focus group methodology, where 36 participants took part in one of eight groups; participants were recruited until saturation of themes was achieved. Three categories of participants were investigated: patients/recent survivors (n= 14); volunteers/advocates (n= 16), the majority of whom were also long-term survivors; and health professionals (n= 6). Focus groups were digitally audio-recorded, transcribed, and coded thematically using NVivo software. Reasons for non-use fell into four broad themes: (1) Resource barriers, particularly the cost and lack of time; (2) fear and distrust, including the potential for drug interactions; (3) lack of evidence, including the unproven nature of many CT practices; and (4) satisfaction with conventional treatment. Two further themes related to the benefits of non-use and reasons for discontinuation. A sub-analysis indicated that reasons for non-use differed by CT category, with non-use being mentioned more frequently for biologically based and body-based therapies. Differences in understanding CT non-use emerged between patients, volunteers and health professionals. Findings have clinical implications regarding tailoring information for patients during and after cancer.
虽然有 50%的癌症患者在治疗期间会使用补充疗法(CT),但很少有研究探讨为什么有些人选择不使用 CT。本研究旨在通过焦点小组方法来解决这一知识空白,共有 36 名参与者参加了 8 个小组中的一个;参与者的招募一直持续到主题达到饱和。研究调查了三类参与者:患者/近期幸存者(n=14);志愿者/倡导者(n=16),其中大多数也是长期幸存者;和卫生专业人员(n=6)。焦点小组进行了数字音频记录、转录,并使用 NVivo 软件进行了主题编码。不使用的原因分为四个广泛的主题:(1)资源障碍,特别是费用和缺乏时间;(2)恐惧和不信任,包括药物相互作用的潜在风险;(3)缺乏证据,包括许多 CT 实践的未经证实的性质;以及(4)对常规治疗的满意。另外两个主题与不使用的好处和停药的原因有关。一项子分析表明,不使用的原因因 CT 类别而异,生物基础和身体基础疗法的不使用被提及得更频繁。患者、志愿者和卫生专业人员之间对 CT 不使用的理解存在差异。这些发现对癌症期间和之后为患者量身定制信息具有临床意义。